Table 1.
Demographics, Clinical Characteristics, and OS.
| Variable | Number | Percentage | Survival Rate | λ2 | P-value | ||
|---|---|---|---|---|---|---|---|
| 1-year | 3-year | 5-year | |||||
| Age, years | 0.55 | 0.96 | |||||
| 0 | 20 | 6.6 | 82.6 | 82.6 | 82.6 | ||
| 1—4 | 55 | 18.3 | 89 | 70.7 | 70.7 | ||
| 5—9 | 26 | 8.6 | 79.2 | 69.3 | 69.3 | ||
| 10—14 | 61 | 20.3 | 96.2 | 75 | 75 | ||
| 15—19 | 139 | 46.2 | 94.9 | 82.5 | 78.8 | ||
| Gender | 0.46 | 0.5 | |||||
| Male | 143 | 47.5 | 97.2 | 86.3 | 81.2 | ||
| Female | 158 | 52.5 | 94.8 | 87.2 | 79.2 | ||
| Race | 3.48 | 0.48 | |||||
| White | 240 | 79.7 | 97.5 | 92.5 | 86.4 | ||
| Black | 41 | 13.6 | 79.3 | 65.7 | 65.7 | ||
| AI | 2 | 0.7 | 50 | —— | —— | ||
| API | 15 | 5.0 | 73.3 | —— | —— | ||
| Unknown | 3 | 1.0 | —— | —— | —— | ||
| Primary site | 44.5 | <0.01 | |||||
| Upper lobe | 81 | 26.9 | 94.7 | 84.2 | 78.3 | ||
| Middle lobe | 27 | 9.0 | 85 | 85 | 85 | ||
| Lower lobe | 100 | 33.2 | 94.9 | 85.9 | 84.1 | ||
| T and B | 40 | 13.3 | 88.4 | 85 | 85 | ||
| Overlapping | 16 | 5.3 | 54.5 | 54.5 | 54.5 | ||
| NOS | 37 | 12.3 | 79.8 | 26.9 | 26.9 | ||
| Laterality | 26.2 | <0.01 | |||||
| Left | 128 | 42.5 | 98.4 | 86.9 | 84 | ||
| Right | 155 | 51.5 | 94.2 | 84.4 | 76.9 | ||
| Bilaterality | 14 | 4.7 | 70.1 | 60.1 | 33.4 | ||
| NOS | 4 | 1.32 | —— | —— | —— | ||
| Location | 60.5 | <0.01 | |||||
| LUL | 48 | 15.9 | 93.1 | 87.7 | 84.8 | ||
| LLL | 43 | 14.3 | 97.5 | 89.8 | 89.8 | ||
| RUL | 31 | 10.3 | 92.9 | 89 | 89 | ||
| RML | 27 | 9.0 | 88.9 | 85 | 85 | ||
| RLL | 57 | 18.9 | 87.4 | 83.1 | 83.1 | ||
| Trachea | 4 | 1.3 | 100 | 100 | 100 | ||
| Bilaterality | 7 | 2.3 | 57.1 | 57.1 | 38.1 | ||
| LM | 24 | 8.0 | 95.8 | 87.1 | 87.1 | ||
| RM | 12 | 4.0 | 100 | 88.9 | 77.8 | ||
| NOS | 32 | 10.6 | 80.2 | 45.1 | 39.4 | ||
| overlapping | 16 | 5.3 | 81.3 | 54.5 | 54.5 | ||
| Histology | 110 | <0.01 | |||||
| Carcinoid tumor | 89 | 29.6 | 97.6 | 97.6 | 97.6 | ||
| MEC | 37 | 12.3 | 97.1 | 97.1 | —— | ||
| Adenocarcinoma | 31 | 10.3 | 78.3 | 55.4 | —— | ||
| SCC | 12 | 4.0 | 20.8 | —— | —— | ||
| NET | 16 | 5.3 | 48.7 | —— | —— | ||
| Pulmonary blastoma | 67 | 22.3 | 93.7 | 77.2 | 70.5 | ||
| Atypical carcinoma | 7 | 2.3 | 100 | —— | —— | ||
| other, NOS | 42 | 14.0 | 84.9 | 43.4 | 34.7 | ||
| Grade | 67.2 | <0.01 | |||||
| I | 53 | 17.6 | 96.2 | 96.2 | —— | ||
| II | 30 | 10.0 | 76.2 | —— | —— | ||
| III | 18 | 6.0 | 36.1 | 11.3 | —— | ||
| IV | 10 | 3.3 | 77.8 | 44.4 | 44.4 | ||
| Unknown | 190 | 63.1 | 97.3 | 93.3 | 85.8 | ||
| Surgery | 100 | <0.01 | |||||
| no | 59 | 19.6 | 89.4 | 47.2 | 23.4 | ||
| yes | 242 | 80.4 | 97.5 | 94.4 | 90.1 | ||
| operation methods | 111 | <0.01 | |||||
| Local tumor destruction or excision | 9 | 3.0 | 88.9 | 76.2 | 76.2 | ||
| sublobar resection | 56 | 18.6 | 98.2 | 94.2 | 89.6 | ||
| Bronchial sleeve resection | 13 | 4.3 | 100 | 100 | 100 | ||
| lobectomy | 120 | 39.9 | 96.6 | 89.8 | 87.2 | ||
| Pneumonectomy | 21 | 7.0 | 75.4 | —— | —— | ||
| Lobe or bilobectomy extended | 16 | 5.3 | 100 | 100 | 100 | ||
| resection NOS | 7 | 2.3 | 100 | 40 | 40 | ||
| TNM stage | 105 | <0.01 | |||||
| I | 65 | 21.6 | 100 | 97.9 | 97.9 | ||
| II | 20 | 6.6 | 100 | 100 | 100 | ||
| III | 24 | 8.0 | 59.7 | —— | —— | ||
| IV | 33 | 11.0 | 74.6 | 34.4 | 13.1 | ||
| unknown | 159 | 52.8 | 97.5 | 87.1 | 81.8 | ||
| Radiotherapy | 1.43 | 0.23 | |||||
| yes | 28 | 9.3 | 75 | —— | —— | ||
| no | 273 | 90.7 | 97.8 | 93.2 | 88 | ||
| Chemotherapy | 108 | <0.01 | |||||
| yes | 112 | 37.2 | 75.9 | 51.7 | 48.1 | ||
| no/unknown | 189 | 62.8 | 98.9 | 96.9 | 96.1 | ||
AI, American Indian/Alaska Native; API, Asian or Pacific Islander; T and B, Trachea and Main bronchus; Overlapping, Overlapping lesion of lung; LUL, left upper lobe; LLL, left lower lobe; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LM, left main bronchus; RM, right main bronchus; MEC, mucoepidermoid carcinoma; SCC, squamous cell carcinoma; NET, neuroendocrine tumor.